PresentationPresentation A Phase 1b Food Effect Study of the First-in-Class, Oral, Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Sarcomas PDF (2.68 MB) Read MorePresentation A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-330 (selinexor) in Patients with Heavily Pretreated Non-Hodgkin’s Lymphoma (NHL) PDF (1.70 MB) Read MorePresentation Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy PDF (2.42 MB) Read MorePresentation Mitochondrial priming of new targeted agents in acute myeloid leukemia PDF (1.19 MB) Read MorePresentation Preclinical efficacy of the novel, oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on castration resistant prostate cancer PDF (1.27 MB) Read MorePresentation Novel activity of selective inhibitors of nuclear export in epithelial-to-mesenchymal transition models PDF (575.79 KB) Read MorePresentation Novel small molecule pak4 allosteric modulators with activity against pancreatic cancer PDF (1.32 MB) Read MorePresentation Selinexor (KPT-330), a novel selective inhibitor of nuclear export (SINE), shows single agent efficacy against alveolar soft part sarcoma (ASPS) in vivo PDF (928.94 KB) Read MorePresentation Safety and Anti-tumor Activity of Selinexor (KPT-330), a First-in-Class, Oral XPO1 Selective Inhibitor of Nuclear Export (SINE) – A Phase I Study Expanded with Colon Cancer Cohort PDF (1.49 MB) Read MorePresentation Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PDF (2.17 MB) Read More Previous 1 … 12 13 14 15 Next